Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemia
- 10 June 2013
- journal article
- clinical trial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 98 (11) , 1697-1701
Abstract
The pharmacokinetics, pharmacodynamics, efficacy and safety of a new recombinant E. coli-asparaginase preparation were evaluated in infants (de novo acute lymphoblastic leukemia. Twelve patients were treated according to the INTERFANT-06 protocol and received up to 10,000 U/m2 recombinant asparaginase as intravenous infusions on days 15, 18, 22, 25, 29 and 33 of remission induction treatment. The asparaginase dose was individually adjusted by protocol to 67% of the calculated dose for infants This trial was registered at www.clinicaltrialsregister.eu as EudraCT number 2008-006300-27).Keywords
This publication has 6 references indexed in Scilit:
- A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-asparaginaseJournal of Clinical Investigation, 2009
- Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trialBlood, 2008
- Acute lymphoblastic leukemia in infancyPediatric Blood & Cancer, 2007
- A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trialThe Lancet, 2007
- Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology GroupBlood, 2006
- The best way to use asparaginase in childhood acute lymphatic leukaemia – still to be defined?British Journal of Haematology, 2004